Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164174 | 0.83 | LMNA (0.43) | PTK2MAPTKDM4EALDH1A1 | |
| SCHEMBL9909935 | 0.79 | NAMPT (0.42) | BRD4NAMPTMAPKAPK2CYP17A1PTGDR2 | |
| SCHEMBL9909933 | 0.77 | KCNJ1 (0.53) | NAMPTCYP17A1BCL2KDM4E | |
| SCHEMBL9909937 | 0.76 | NAMPT (0.49) | NAMPTMAPKAPK2CYP17A1PSMB8MAP4K4 | |
| SCHEMBL30208803 | 0.75 | NAMPT (0.56) | NAMPTMAPKAPK2CYP17A1PTGDR2CA12 | |
| SCHEMBL376258 | 0.75 | NAMPT (0.56) | NAMPTMAPKAPK2CYP17A1PTGDR2CA12 | |
| SCHEMBL1984304 | 0.74 | TRPV1 (0.57) | NAMPTMAPTKDM4EALDH1A1WNT3A | |
| SCHEMBL9909932 | 0.72 | LMNA (0.53) | NAMPTCYP17A1MAP4K4MAPTKDM4E | |
| SCHEMBL29301634 | 0.72 | MAPT (0.61) | MAPTWNT3A | |
| SCHEMBL24896788 | 0.72 | NAMPT (0.41) | BRD4NAMPTMAPKAPK2CYP17A1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464228-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, GCGR | BRD4 2506/4885NAMPT 2670/4885MAPKAPK2 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.